Illuminations (a) and attenuation rates (b) of the RVL along the axis of y = 0 m at different angles. by Fei Li (143236)

Subjects:

Illuminations (a) and attenuation rates (b) of the RHL along the axis of y = 0 m at different angles. by Fei Li (143236)

Subjects:

Illuminations (a) and attenuation rates (b) of the CL along the axis of y = 0 m at different angles. by Fei Li (143236)

Subjects:

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

The differences in illumination (a-c) and their three-dimensional distributions (d-f) between RVL and RHL at different angles. by Fei Li (143236)

Subjects:

The differences in illumination (a-c) and their three-dimensional distributions (d-f) between RVL and CL at different angles. by Fei Li (143236)

Subjects:

Illumination distributions (a-c) and variations in illuminance values along the x-axis (d-f) of the CL at different angles. by Fei Li (143236)

Subjects:

Illumination distributions (a-c) and variations in illuminance values along the x-axis (d-f) of the RHL at different angles. by Fei Li (143236)

Subjects:

Why does task performance decrease with burst length? by Swathi Anil (17382903)

In individuals affected by PCA, there is a significant downregulation of genes associated with the cholesterol biosynthetic pathway. by Leemon Nikhila (22250736)

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Illumination distributions (a-c) and variations in illuminance values along the <i>x</i>-axis (d-f) of the RVL at different angles. by Fei Li (143236)

Subjects:

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

Results of significance for regression factors. by Junxia Zhou (14381598)

“…Micro-cracks appeared in the cemented body by Day 7, resulting in a slight decrease in strength (3.92%) from Day 3 to Day 7. …”